European regulators have moved to add the results of the landmark Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results